Lipella Pharmaceuticals Accounts Payable

Lipella Pharmaceuticals posts a accounts payable of $460M as of September 2025. That compares with $460M in the prior-year period — up 0.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Lipella Pharmaceuticals's accounts payable was $460M. The latest reading is $460M — a 0.7% year-over-year increase (period ending September 2025). Use the history and growth charts on this page for a longer lookback.

Accounts Payable is one piece of Lipella Pharmaceuticals's financial statement story. At $460M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LIPO's accounts payable usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Lipella Pharmaceuticals's other metric pages and overview cover the third.